Issue

Vol. 27 No. 12 (2015): Vol 27 Issue 12

Copyright (c) 2015 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

RP-UPLC-MS Assay Method for Eltrombopag: Application in Pharmaceuticals, Human Plasma and Urine Samples

https://doi.org/10.14233/ajchem.2015.19252
D. Mahaboob Basha
Research and Development Center, Bharathiar University, Coimbatore-641 046, India
G. Venkata Reddy
Research and Development Center, Bharathiar University, Coimbatore-641 046, India
T. Shobha Rani
Department of Chemistry, Dravidian University, Kuppam, Chittoor-517 426, India
E. Susithra
Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai-600 116, India
Rajasekhar Chekkara
Department of Chemistry, Sathyabama University, Jeppiaar Nagar, Chennai-600 119, India

Corresponding Author(s) : D. Mahaboob Basha

ahmad_mahaboob@yahoo.co.in

Asian Journal of Chemistry, Vol. 27 No. 12 (2015): Vol 27 Issue 12

Abstract

A simple, accurate, rapid and precise method was developed using UPLC coupled to mass detector (UPLC-MS) for stability and estimation of eltrombopag (EMP) in its bulk and dosage forms, human plasma and urine samples. Instrumentation used for this method was highly sophisticated and of superior technology in terms of speed, separation, solvent usage and analysis cost. The efficient separation of drug from its degradation products was achieved by using Acquity UPLC BEH column C18 (50 × 2.1 mm, 1.7 μm) with linear gradient elution of mobile phase (0.1 % formic acid in water & acetonitrile) 97:03 % v/v at initial gradient and flow rate of 0.6 mL/min. The chromatogram was analyzed at a wavelength of 230 nm (lmax) using PDA detector and further confirmed by mass (m/z) using waters SQD (Single Quadrapole Detector-3100 mass range 100 amu-1000 amu) with a run time of 4.5 min. The linearity range was performed from 20 to 100 μg/mL (R2 = 0.999) with regression of y = 433.88x + 35.4. The variation of precision study was found to be < 1 %. Eltrombopag was showing more sensitivity towards the acidic degradation. The formed degradative products were identified by mass spectrometry (UPLC-MS) and the mode of degradation was reported. The dosage form and bulk drug samples were subjected to forced degradation and analyzed as per ICH Q1A (R2) and Q2 (R1) guidelines.

Keywords

Eltrombopag UPLC Mass spectrometry Forced degradation ICH
Mahaboob Basha, D., Venkata Reddy, G., Shobha Rani, T., Susithra, E., & Chekkara, R. (2015). RP-UPLC-MS Assay Method for Eltrombopag: Application in Pharmaceuticals, Human Plasma and Urine Samples. Asian Journal of Chemistry, 27(12), 4615–4619. https://doi.org/10.14233/ajchem.2015.19252
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Y. Deng, A. Madatian, M.B. Wire, C. Bowen, J.W. Park, D. Williams, B. Peng, E. Schubert, F. Gorycki, M. Levy and P.D. Gorycki, Drug Metab. Dispos., 39, 1734 (2011); doi:10.1124/dmd.111.040170.
  2. A.J. Allred, C.J. Bowen, J.W. Park, B. Peng, D.D. Williams, M.B. Wire and E. Lee, Br. J. Clin. Pharmacol., 72, 321 (2011); doi:10.1111/j.1365-2125.2011.03972.x.
  3. J.B. Bussel, D. Provan, T. Shamsi, G. Cheng, B. Psaila, L. Kovaleva, A. Salama, J.M. Jenkins, D. Roychowdhury, B. Mayer, N. Stone and M. Arning, Lancet, 373, 641 (2009); doi:10.1016/S0140-6736(09)60402-5.
  4. J.B. Bussel, G. Cheng, M.N. Saleh, B. Psaila, L. Kovaleva, B. Meddeb, J. Kloczko, H. Hassani, B. Mayer, N.L. Stone, M. Arning, D. Provan and J.M. Jenkins, N. Engl. J. Med., 357, 2237 (2007); doi:10.1056/NEJMoa073275.
  5. J.G. McHutchison, G. Dusheiko, M.L. Shiffman, M. Rodriguez-Torres, S. Sigal, M. Bourliere, T. Berg, S.C. Gordon, F.M. Campbell, D. Theodore, N. Blackman, J. Jenkins and N.H. Afdhal, N. Engl. J. Med., 357, 2227 (2007); doi:10.1056/NEJMoa073255.
  6. G. Cheng, Ther. Adv. Hematol., 3, 155 (2012); doi:10.1177/2040620712442525.
  7. R. Maddela, R. Gajula, N.R. Pilli, S. Siddiraju, S. Maddela and A. Makula, J. Pharm. Biomed. Anal., 98, 68 (2014); doi:10.1016/j.jpba.2014.04.028.
  8. E. Tablets, Revolade®, GlaxoSmithKline Inc., pp. 1-59 (2014).
  9. K.P. Garnock-Jones, BioDrugs, 25, 401 (2011); doi:10.2165/11207620-000000000-00000.
  10. V.P. Patil, R.D. Tathe, S.J. Devdhe, S.S. Angadi and S.H. Kale, Int. Res. J. Pharm., 2, 39 (2011).
  11. J.M. Jenkins, D. Williams, Y. Deng, J. Uhl, V. Kitchen, D. Collins and C.L. Erickson-Miller, Blood. PubMed., 109, 4739 (2007); doi:10.1182/blood-2006-11-057968.
  12. T. Kawaguchi, A. Komori, M. Seike, S. Fujiyama, H. Watanabe, M. Tanaka, S. Sak-isaka, M. Nakamuta, Y. Sasaki, M. Oketani, T. Hattori, K. Katsura and M. Sata, J. Gastroenterol., 47, 1342 (2012); doi:10.1007/s00535-012-0600-5.
  13. V.L. Serebruany, C. Eisert, E. Sabaeva and L. Makarov, Am. J. Ther., 17, 68 (2010); doi:10.1097/MJT.0b013e318199d6b7.
  14. ICH Stability Testing of New Drug Substances and Products Q1A (R2), In: Proceedings of International Conference on Harmonization, Geneva (2003).
  15. ICH Validation of Analytical Procedures, Text and Methodology Q2 (R1), In: Proceedings of International Conference on Harmonization (2005).
  16. R.R. Kondeti, K.S. Mulpuri and B. Meruga, World. J. Pharm. Sci., 2, 1375 (2014).
  17. Waters Corporation, ACQUITY UPLC System Quick Start Guide, 71500082503, Revision C (2006).
  18. Waters Corporation, Waters SQ Detector, Operator’s Guide, Revision E (2006).
  19. B. Srivastava, B.K. Sharma and B.U. Singh, Int. J. Pharm. Qual. Assur. Pharm. Anal., 2, 19 (2010).
  20. K.H. Carpenter and V. Wiley, Clin. Chim. Acta, 322, 1 (2002); doi:10.1016/S0009-8981(02)00135-3.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0